Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Prothena Corporation plc - Ordinary Shares (NQ:PRTA)

9.000 -0.250 (-2.70%)
Streaming Delayed Price Updated: 11:55 AM EDT, Aug 27, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Prothena Corporation plc - Ordinary Shares

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Prothena (NASDAQ:PRTA) Beats EPS but Misses Revenue in Mixed Q2 2026 Results ↗
Via Chartmill
News headline image
Prothena Reports Second Quarter 2026 Financial Results and Business Highlights
From Prothena Corporation plc
Via Business Wire
News headline image
Prothena to Report Second Quarter 2026 Financial Results on August 6
From Prothena Corporation plc
Via Business Wire
Prothena (NASDAQ:PRTA) Smashes Q1 Estimates on $50 Million Milestone Payment, Shares Steady ↗
Via Chartmill
News headline image
Prothena Reports First Quarter 2026 Financial Results and Business Highlights
From Prothena Corporation plc
Via Business Wire
News headline image
Prothena to Report First Quarter 2026 Financial Results on May 7
From Prothena Corporation plc
Via Business Wire
Prothena Corporation (NASDAQ:PRTA) Reports Q4 2025 Revenue Miss, Highlights Pipeline Progress and 2026 Cash Guidance ↗
Via Chartmill
News headline image
Earnings Scheduled For November 6, 2025 ↗
 
Via Benzinga
What's going on in today's after hours session ↗
Via Chartmill
News headline image
Prothena Announces Novo Nordisk Obtains Fast Track Designation from the U.S. FDA for Coramitug (PRX004) in ATTR Amyloidosis with Cardiomyopathy
From Prothena Corporation plc
Via Business Wire
News headline image
Prothena Announces Leadership Team Updates
From Prothena Corporation plc
Via Business Wire
News headline image
Prothena Partners Present Data Supporting Next Generation Treatments for Parkinson’s and Alzheimer’s Disease at AD/PD™ 2026
From Prothena Corporation plc
Via Business Wire
News headline image
Prothena Announces Achievement of $50 Million Clinical Milestone Payment from Novo Nordisk Related to Ongoing Phase 3 Clinical Trial for Coramitug (Formerly PRX004) in ATTR Amyloidosis with Cardiomyopathy
From Prothena Corporation plc
Via Business Wire
News headline image
Prothena Announces up to $100 Million Share Repurchase Plan
From Prothena Corporation plc
Via Business Wire
News headline image
Prothena Reports Fourth Quarter and Full Year 2025 Financial Results, and Provides Financial Guidance and Business Highlights
From Prothena Corporation plc
Via Business Wire
News headline image
Prothena to Report Fourth Quarter and Full Year 2025 Financial Results on February 19, 2026
From Prothena Corporation plc
Via Business Wire
News headline image
Prothena Announces Board of Directors Update
From Prothena Corporation plc
Via Business Wire
News headline image
Prothena Announces Poster Presentation on its TDP-43 CYTOPE® Program at Neuroscience 2025
From Prothena Corporation plc
Via Business Wire
News headline image
Novo Nordisk's $100 Million Coramitug Shows Promise In Reducing Heart Failure Biomarker ↗
Novo Nordisk's Coramitug cut NT-proBNP levels and was well tolerated in a Phase 2 ATTR-CM trial, paving the way for its Phase 3 CLEOPATTRA study. 
Via Benzinga
News headline image
Prothena Highlights Phase 2 Data for Coramitug (Formerly PRX004) Published in Circulation, Official Journal of AHA
From Prothena Corporation plc
Via Business Wire
News headline image
Prothena Corp PLC (NASDAQ:PRTA) Reports Q3 2025 Earnings and Key Pipeline Milestones ↗
Prothena reports Q3 2025 earnings, provides updates on its neurodegenerative disease pipeline, and reaffirms strong cash position. 
Via Chartmill
News headline image
Prothena Reports Third Quarter 2025 Financial Results and Business Highlights
From Prothena Corporation plc
Via Business Wire
News headline image
Prothena to Report Third Quarter 2025 Financial Results on November 6
From Prothena Corporation plc
Via Business Wire
News headline image
Deep Dive Into Prothena Corp Stock: Analyst Perspectives (7 Ratings) ↗
 
Via Benzinga
News headline image
Prothena’s Partner Bristol Myers Squibb Obtains Fast Track Designation from the U.S. FDA for BMS-986446 (PRX005), an Anti-MTBR-Tau-Targeting Antibody, for the Treatment of Alzheimer’s Disease
From Prothena Corporation plc
Via Business Wire
News headline image
Alibaba To Rally More Than 12%? Here Are 10 Top Analyst Forecasts For Tuesday ↗
 
Via Benzinga
News headline image
FDA Tightens Safety Guidelines For Biogen Leqembi Alzheimer's Therapy ↗
The FDA now requires earlier MRI screening for Alzheimer's drug Leqembi to detect ARIA-E, a rare but serious side effect, aiming to improve treatment safety for patients. 
Via Benzinga
News headline image
Prothena to Participate in the Cantor Fitzgerald Global Healthcare Conference
From Prothena Corporation plc
Via Business Wire
News headline image
Prothena Reports Non-Competitive Brain Swelling Rates In Early Alzheimer's Study ↗
Prothena reported ASCENT trial data showing strong amyloid plaque reduction but high ARIA-E rates for Alzheimer's drug PRX012, prompting a shift in focus. 
Via Benzinga
News headline image
What 4 Analyst Ratings Have To Say About Prothena Corp ↗
 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.